1929 related articles for article (PubMed ID: 18571246)
21. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
22. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
Sukasem C; Churdboonchart V; Chasombat S; Kohreanudom S; Watitpun C; Pasomsub E; Piroj W; Tiensuwan M; Chantratita W
Infection; 2007 Apr; 35(2):81-8. PubMed ID: 17401711
[TBL] [Abstract][Full Text] [Related]
23. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
24. Antiretroviral drugs in the treatment of people living with human immunodeficiency virus: experience in a south Indian tertiary referral centre.
Kumarasamy N; Solomon S; Peters E; Amalraj RE; Purnima M; Ravikumar B; Yepthomi T; Thyagarajan SP
J Assoc Physicians India; 2000 Apr; 48(4):390-3. PubMed ID: 11273171
[TBL] [Abstract][Full Text] [Related]
25. Sequencing of antiretroviral therapy in children in low- and middle-income countries.
Sohn AH; Nuttall JJ; Zhang F
Curr Opin HIV AIDS; 2010 Jan; 5(1):54-60. PubMed ID: 20046148
[TBL] [Abstract][Full Text] [Related]
26. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
[TBL] [Abstract][Full Text] [Related]
27. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
Youle M
J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
[TBL] [Abstract][Full Text] [Related]
28. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
Orsi F; d'almeida C
Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral treatment of HIV infection: Swedish recommendations 2007.
Josephson F; Albert J; Flamholc L; Gisslén M; Karlström O; Lindgren SR; Navér L; Sandström E; Svedhem-Johansson V; Svennerholm B; Sönnerborg A
Scand J Infect Dis; 2007; 39(6-7):486-507. PubMed ID: 17577810
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.
Notari S; Bocedi A; Ippolito G; Narciso P; Pucillo LP; Tossini G; Donnorso RP; Gasparrini F; Ascenzi P
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):258-66. PubMed ID: 16406832
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
Menéndez-Arias L; Alvarez M
Antiviral Res; 2014 Feb; 102():70-86. PubMed ID: 24345729
[TBL] [Abstract][Full Text] [Related]
32. [AIDS; new developments. II. Treatment of HIV infection].
Borleffs JC; Esseveld F; Hoepelman IM; Boucher CA
Ned Tijdschr Geneeskd; 1997 May; 141(21):1036-43. PubMed ID: 9340560
[TBL] [Abstract][Full Text] [Related]
33. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.
Jiménez-Nácher I; García B; Barreiro P; Rodriguez-Novoa S; Morello J; González-Lahoz J; de Mendoza C; Soriano V
J Antimicrob Chemother; 2008 Oct; 62(4):816-22. PubMed ID: 18567912
[TBL] [Abstract][Full Text] [Related]
34. Emerging anti-HIV drugs.
De Clercq E
Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
[TBL] [Abstract][Full Text] [Related]
35. Current and future management of treatment failure in low- and middle-income countries.
Boyd MA
Curr Opin HIV AIDS; 2010 Jan; 5(1):83-9. PubMed ID: 20046152
[TBL] [Abstract][Full Text] [Related]
36. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
37. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Paredes R; Tzou PL; van Zyl G; Barrow G; Camacho R; Carmona S; Grant PM; Gupta RK; Hamers RL; Harrigan PR; Jordan MR; Kantor R; Katzenstein DA; Kuritzkes DR; Maldarelli F; Otelea D; Wallis CL; Schapiro JM; Shafer RW
PLoS One; 2017; 12(7):e0181357. PubMed ID: 28753637
[TBL] [Abstract][Full Text] [Related]
38. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
39. New developments in HIV drug resistance.
Cane PA
J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
[TBL] [Abstract][Full Text] [Related]
40. HIV resistance and the developing world.
Gupta RK; Pillay D
Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
